logo
Plus   Neg
Share
Email

FDA Grants Priority Review For Novartis' Sickle Cell Medicine Crizanlizumab

Novartis (NVS) said Tuesday that the US Food and Drug Administration accepted the company's Biologics License Application or BLA and granted Priority Review for its investigational sickle cell medicine crizanlizumab or SEG101.

If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.

Sickle cell disease is a debilitating inherited genetic blood disorder that affects the shape of the red blood cells and can make blood cells and blood vessels stickier than usual.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the third quarter on Thursday, branded food company Hormel Foods Corp. (HRL) reaffirms its earnings guidance for the full-year 2019, while trimming annual net sales outlook as its navigates near-term uncertainty related to African swine fever. For fiscal 2019,... The U.S. Food and Drug Administration has issued a warning letter to Ningbo Huize Commodity Co., an over-the-counter drug manufacturer, for significant current good manufacturing practice violations, including data integrity issues. The warning letter issued to Ningbo Huize details a failure to have... Crate and Barrel have recalled 1,500 push walkers due to risk of choking and laceration. Crate and Barrel have recalled Activity Push Walkers as those walkers can be damaged over time exposing sharp points and small parts, posing choking and laceration hazards to small children. The wooden recalled...
Follow RTT